Advanced search: Search from
Select basic information for advanced search
| Free word |
|---|
| Details |  |
|---|---|
| Related links |  |
| Search |  |
Rchr
J-GLOBAL ID：202401014215500418
Update date: Mar. 22, 2025 AZUMA KOICHI
アズマ コウイチ | AZUMA KOICHI
ClipsMISC (12)
- Takeharu Ono, Koichi Azuma, Akihiko Kawahara, Tetsuro Sasada, Satoshi Hattori, Fumihiko Sato, Shun-Ich Chitose, Buichiro Shin, Jun Akiba, Hirohito Umeno. Relevance between PD-L1 expression combined with tumor infiltrating lymphocytes and prognosis in advanced hypopharyngeal squamous cell carcinoma. JOURNAL OF CLINICAL ONCOLOGY. 2017. 35
- Hayato Kaida, Koichi Azuma, Akihiko Kawahara, Eiji Sadashima, Satoshi Hattori, Jun Akiba, Axel Rominger, Shinzo Takamori, Kiminori Fujimoto, Makoto Hosono, et al. Prognostic impact of F-18-FDG PET parameters and molecular markers expression in resected non-small cell lung cancer patients. JOURNAL OF NUCLEAR MEDICINE. 2017. 58
- Yuichi Takiguchi, Toyoaki Hida, Hiroshi Nokihara, Masashi Kondo, Young Hak Kim, Koichi Azuma, Takashi Seto, Makoto Nishio, Hiroshige Yoshioka, Fumio Imamura, et al. Updated efficacy and safety of the j-alex study comparing alectinib (ALC) with crizotinib (CRZ) in ALK-inhibitor naive ALK fusion positive non-small cell lung cancer (ALK plus NSCLC). JOURNAL OF CLINICAL ONCOLOGY. 2017. 35
- Norikazu Matsuo, Koichi Azuma, Kazuko Sakai, Akihiko Kawahara, Hidenobu Ishii, Takaaki Tokito, Takashi Kinoshita, Kazuhiko Yamada, Kazuto Nishio, Tomoaki Hoshino. Association of EGFR Exon 19 Deletion and EGFR-TKI treatment duration with Frequency of T790M Mutation in EGFR-Mutant Lung Cancer Patients. JOURNAL OF THORACIC ONCOLOGY. 2017. 12. 1. S1201-S1202
- Toshio Shimizu, Hiroshi Nokihara, Haruyasu Murakami, Takashi Seto, Makoto Nishio, Koji Takeda, Akira Inoue, Katsuyuki Kiura, Koichi Azuma, Anne Keating, et al. Phase I/II study of ASP8273 in patients with non-small-cell lung cancer (NSCLC) harboring EGFR activating mutations. ANNALS OF ONCOLOGY. 2015. 26. 82-82
- Takashi Seto, Masayuki Takeda, Hidetoshi Hayashi, Koichi Azuma, Morihito Okada, Shunichi Sugawara, Takeharu Yamanaka, Kazuhiko Nakagawa, Yoichi Nakanishi, Isamu Okamoto. Bevacizumab beyond disease progression in advanced non-squamous NSCLC (WJOG 5910L): a randomized phase II trial. ANNALS OF ONCOLOGY. 2015. 26. 91-91
- Eiji Iwama, Kazuko Sakai, Koichi Azuma, Kaname Nozaki, Daijiro Harada, Katsuyuki Hotta, Fumiyoshi Ohyanagi, Yoichi Nakanishi, Kazuto Nishio, Isamu Okamoto. A prospective biomarker study in afatinib-treated patients with EGFR-mutation positive non-small cell lung. ANNALS OF ONCOLOGY. 2015. 26. 83-83
- Hidenobu Ishii, Koichi Azuma, Kazuko Sakai, Takaaki Tokito, Kazuhiko Yamada, Kazuto Nishio, Tomoaki Hoshibo. Noninvasive detection of acquired T790M mutation in NSCLC patients treated with EGFR-TKI using digital PCR of plasma. ANNALS OF ONCOLOGY. 2015. 26. 138-138
- Hidenobu Ishii, Koichi Azuma, Kazuko Sakai, Takaaki Tokito, Kazuhiko Yamada, Kazuto Nishio, Tomoaki Hoshino. Digital PCR Analysis of Plasma Cell-Free DNA as a Noninvasive Detection of the Drug Resistance Mechanisms in EGFR Mutant NSCLC. JOURNAL OF THORACIC ONCOLOGY. 2015. 10. 9. S605-S606
- Koichi Azuma, Eiji Iwama, Kazuko Sakai, Kaname Nozaki, Daijiro Harada, Katsuyuki Hotta, Fumiyoshi Ohyanagi, Takayasu Kurata, Hiroaki Akamatsu, Koichi Goto, et al. A Multicenter Prospective Biomarker Study in Afatinib-Treated Patients with EGFR-Mutation Positive Non-Small Cell Lung Cancer. JOURNAL OF THORACIC ONCOLOGY. 2015. 10. 9. S299-S299
- Masayuki Takeda, Takashi Seto, Hidetoshi Hayashi, Morihito Okada, Koichi Azuma, Shunichi Sugawara, Haruko Daga, Tomonori Hirashima, Kimio Yonesaka, Yoshiko Urata, et al. Bevacizumab beyond disease progression after first-line treatment with bevacizumab plus chemotherapy inadvanced nonsquamous non-small cell lung cancer (WJOG 5910L): An open-label, randomized, phase II trial. JOURNAL OF CLINICAL ONCOLOGY. 2015. 33. 15
- Koichi Azuma, Akihiko Kawahara, Kahori Sonoda, Kazutaka Nakashima, Kousuke Tashiro, Kosuke Watari, Hiroto Izumi, Masayoshi Kage, Michihiko Kuwano, Mayumi Ono, et al. FGFR1 activation is an escape mechanism in human lung cancer cells resistant to afatinib, a pan-EGFR family kinase inhibitor. Oncotarget. 2014. 5. 15. 5908-5919
1 to 12 of 12 results
- « Top
- ‹ Prev
- 1
- Next ›
- Last »
